{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-022658","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2024-07-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.038381+00:00","generated_at":"2026-05-31T20:56:12.928712+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024","bullets":["Phase 2b RewinD-LB trial of neflamapimod for dementia with Lewy bodies fully enrolled; topline data expected December 2024.","KOL event on July 23, 2024 features John-Paul Taylor (Newcastle Univ.) and Ralph A. Nixon (NYU Grossman School of Medicine).","Agenda includes DLB disease state, neflamapimod mechanism, plasma phosphorylated tau patient selection, and trial design.","Live Q&A session moderated by CervoMed CEO John Alam following the formal presentations."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-022658","json":"https://secwatch.observer/filing/0001437749-24-022658.json","markdown":"https://secwatch.observer/filing/0001437749-24-022658.md","text":"https://secwatch.observer/filing/0001437749-24-022658.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774924022658/0001437749-24-022658-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774924022658/crvo20240711_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T20:56:12.928712+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}